The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

AUTHORS

Nasser Ebrahimi Daryani 1 , * , Babak Haghpanah 2 , Ali Reza Sayyah 2 , Ali Asad Hashtroudi 2 , Mohammad Bashashati 2 , Parisa Poursamimi 2 , Mehri Nikbin 2

1 Tehran University of Medical Sciences, Imam Khomeini Hospital & Study Group of Interferon in Iran (SG.IFN.IR), [email protected], Tehran, IR.Iran

2 Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, IR.Iran

How to Cite: Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial, Hepat Mon. Online ahead of Print ; 4(7):71-74.

ARTICLE INFORMATION

Hepatitis Monthly: 4 (7); 71-74
Article Type: Research Article

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and aims: Peginterferon alpha-2a is a known standard therapy for patients with chronic HCV infection. However efficacy and safety of this treatment is still unclear in regional settings. This study was designed to clarify efficacy and safety of peg-interferon based therapy in Iranian patients.
Methods: 23 patients were treated with Peginterferon alpha-2a in combination with ribavirin for 48 weeks. The patients were observed for adverse effects and response to therapy during treatment and 24 weeks after the end of therapy.
Results: Early virologic response, end of treatment response, and sustained virologic response rates were 86.9 % (20/23), 82.6 % (19/23), and 78.3 % (18/23) respectively. The most common adverse effects in descending order were flue-like symptoms (74%), mood changes (48%), and weight loss (43%). 
Conclusion: Combination therapy with Peginterferon alpha-2a and ribavirin for 48 weeks is an effective treatment with minimal adverse effects.

Keywords

Hepatitis C, Pegylated interferon-alpha-2a, Ribavirin, Therapy

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: